Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness. The company's Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California.
Industry, Sector and Symbol
Industry General industrial machinery,
Sub-IndustryN/A
SectorMedical
Phone510-984-1761
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.35 million
Profitability
Miscellaneous
Employees92
OptionableNot Optionable
Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions
What is Ekso Bionics' stock symbol?
Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."
When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work?
Shares of Ekso Bionics reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.
How were Ekso Bionics' earnings last quarter?
Ekso Bionics Holdings Inc (NASDAQ:EKSO) issued its quarterly earnings data on Wednesday, November, 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.02. The firm had revenue of $2.55 million for the quarter, compared to the consensus estimate of $2.86 million. Ekso Bionics had a negative net margin of 303.58% and a negative return on equity of 257.70%. View Ekso Bionics' Earnings History.
When is Ekso Bionics' next earnings date?
Has Ekso Bionics been receiving favorable news coverage?
News stories about EKSO stock have been trending somewhat positive on Sunday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ekso Bionics earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future.
Who are some of Ekso Bionics' key competitors?
Some companies that are related to Ekso Bionics include Synthorx (THOR), ProQR Therapeutics (PRQR), Pharming Group (PHGUF), CONSORT Med PLC/S (CSRMY), Establishment Labs (ESTA), Prothena (PRTA), BioSpecifics Technologies (BSTC), GlycoMimetics (GLYC), Corbus Pharmaceuticals (CRBP), Antares Pharma (ATRS), Medical Facilities (DR), Eidos Therapeutics (EIDX), Arcus Biosciences (RCUS), Zymeworks (ZYME) and LeMaitre Vascular (LMAT).
Who are Ekso Bionics' key executives?
Ekso Bionics' management team includes the folowing people:
- Mr. Steven A. Sherman, Exec. Chairman (Age 73)
- Mr. Jack Peurach, Pres, CEO & Director (Age 53)
- Mr. John F. Glenn, CFO & Sec. (Age 57)
- Ms. Foon Lim Chwee, Pres of APAC
- Mr. Matthias Stief, Managing Director of Ekso Bionics Europe GmbH
Who are Ekso Bionics' major shareholders?
Ekso Bionics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (0.17%), Virtu Financial LLC (0.12%), Northern Trust Corp (0.11%) and Bank of New York Mellon Corp (0.10%). Company insiders that own Ekso Bionics stock include Amy Mcbride Wendell, Max Scheder-Bieschin, Russ Angold, Steven Sherman and Thomas Looby. View Institutional Ownership Trends for Ekso Bionics.
Which major investors are selling Ekso Bionics stock?
Which major investors are buying Ekso Bionics stock?
EKSO stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC and Bank of New York Mellon Corp. Company insiders that have bought Ekso Bionics stock in the last two years include Amy Mcbride Wendell, Max Scheder-Bieschin, Steven Sherman and Thomas Looby. View Insider Buying and Selling for Ekso Bionics.
How do I buy shares of Ekso Bionics?
Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ekso Bionics' stock price today?
One share of EKSO stock can currently be purchased for approximately $2.18.
How big of a company is Ekso Bionics?
Ekso Bionics has a market capitalization of $136.56 million and generates $7.35 million in revenue each year. The company earns $-29,120,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Ekso Bionics employs 92 workers across the globe.
What is Ekso Bionics' official website?
How can I contact Ekso Bionics?
Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]
MarketBeat Community Rating for Ekso Bionics (NASDAQ EKSO)
MarketBeat's community ratings are surveys of what our community members think about Ekso Bionics and other stocks. Vote "Outperform" if you believe EKSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
